Thursday, June 9, 2016

TheStreet: Jim Cramer Looks at Beer Stocks - Anheuser-Busch InBev , Molson Coors and Constellation Brands

Published on 8 Jun 2016
Anheuser-Busch InBev , Molson Coors and Constellation Brands should be purchased because there is massive consolidation in the beer industry, says TheStreet's Jim Cramer. He said he knows firsthand because people are demanding more and more beer at his bar in Brooklyn. Cramer says being a beer distributor right now is one of the most lucrative opportunities around. And if he had to choose a beer to drink, Cramer said he prefers Coors Light and Corona Light.
Posted by at No comments:

#Lebanon - Beirut Hackathon Aims to Bring Tech Innovations to Refugees: Wall Street Journal

Published on 8 Jun 2016
At a hackathon in Beirut in early June, 12 teams worked 48 hours straight to try and develop apps and tech solutions for the U.N. that could help better manage the Middle East's refugee crisis.
Posted by at No comments:

#Syria - Deadly air strikes hit Aleppo hospital: Al Jazeera English

Published on 8 Jun 2016
The UN has issued a strong condemnation, after three hospitals in rebel held areas of the Syrian city of Aleppo were attacked in the space of three hours.

At least twenty people were killed in airstrikes on the neighbourhood of Al-Shaar.
Many children were among the injured.

Al Jazeera's Osama Bin Javaid's reports.
Posted by at No comments:

ReNeuron (LON:RENE) making good progress in clinical trial, says CFO: ProactiveInvestors Stocktube

Published on 8 Jun 2016
The third patient in stem cell specialist ReNeuron Group Plc’s (LON:RENE) early-stage clinical trial treating people with a rare eye disease will receive the therapy next week. 

Researchers at Massachusetts Eye and Ear in Boston are using human retinal progenitor cells (hRPC) to possibly halt the progression of retinitis pigmentosa (RP).

Michael Hunt, chief financial officer, tells Proactive Investors “it’s important because the third patient marks the end of the first dose cohort in this particular study…so that’s good progression”.

They are carrying out a phase I/II clinical study on 15 acute sufferers of the degenerative conditions, and hunt says he expects the rest to be completed “over the course of this and possibly a little bit into next year” depending on the recruitment process.

www.reneuron.com/
http://www.4-traders.com/RENEURON-GROUP-PLC-4005458/
www.proactiveinvestors.co.uk › LON:RENE

Posted by at No comments:

#USA - New Information About Brock Turner Revealed: ABC News

Published on 8 Jun 2016
In letters to the judge, the former Stanford student said he "never really experienced. . .partying that involved alcohol", but new pictures and text messages appear to show Turner using drugs and alcohol before college
Posted by at No comments:

Trading Video: NZD/USD Rallies After RBNZ, S&P 500 Keeps Crawling to New Highs: Forex News by DailyFX

Published on 8 Jun 2016
Talking Points:

• Risk appetite trends continues to mark time with a slow but steady climb led by yet another S&P 500 11-month high
• The Dollar's tumble has run short on steam as we officially enter the communications blackout pre-FOMC
• NZD is this morning's top mover with an RBNZ hold that sent the currency soaring - the question is does it last?

Read the full article here:
https://www.dailyfx.com/forex/video/d...
Posted by at No comments:

Wednesday, June 8, 2016

#Israel - Death toll from mass shooting in central Tel Aviv rises to at least 3, several injured: BNO News

Published on 8 Jun 2016
Security forces and ambulances are responding to a mass shooting at Sarona Market in central Tel Aviv, officials say. At least three people have been confirmed dead, according to Channel 10 and other Israeli media. As many as nine people have been injured and two suspects have been taken into custody. James Valles reporting (BNO News)
Posted by at No comments:

ValiRx (LON:VAL) in talks over cancer drug collaborations, says chief: ProactiveInvestors Stocktube

Published on 8 Jun 2016
Satu Vainikka, chief executive of ValiRx Plc (LON:VAL), tells Proactive Investors the company is discussions with larger companies over potential licencing deals and collaborations for its lead cancer drug VAL 201.

The company is to broaden the phase I/II clinical trial of its lead cancer drug to speed up the dose expansion stage, allowing it to complete the prostate cancer trial within the projected and regulatory-agreed time frame.
“A biotech business model is to take things from A to B and once you start reaching B, which in our case is Phase II clinical trials, we are starting to talk to big pharmaceutical companies or bigger biotech companies,” Vainikka says.

The company has also started preparatory work on a full efficacy study (phase III) of the drug in prostate cancer treatment.

www.valirx.com/
 www.proactiveinvestors.com/LON:VAL/ValiRx
http://www.4-traders.com/VALIRX-PLC-22619385/
Posted by at No comments:
Subscribe to: Posts (Atom)